Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
A look at 3 forms of fatty liver disease: Non-Alcoholic Fatty Liver, Non-Alcoholic Fatty Liver Disease, and Non-Alcoholic Steatohepatitis
Using a two-part testing plan could help identify those with advanced liver fibrosis among people with type 2 diabetes.
Many people with fatty liver disease have obesity, diabetes and other metabolic conditions.
People with advanced liver cirrhosis are at greater risk for severe COVID-19 illness and death.
Researchers reported significant changes in liver, cardiovascular and diabetes markers.
Researchers recommend screening for fatty liver disease within this population.
As with HIV-negative individuals, non-alcoholic fatty liver disease is tied to diabetes and irregular blood lipids in those with HIV.
A fifth of the worldwide population with fatty liver disease consists of lean people.
The profile of chronic liver disease has changed due to obesity trends and advances in the treatment of hepatitis C.
The injectable hormone helps reduce inflammation and fibrosis associated with NAFLD in this population.
Studies of PPAR agonists have yielded mixed results for people with fatty liver disease.
Obesity increased the risk of liver disease to a smaller extent, according to a meta-analysis study.
The regulatory agency requested further data to show whether its benefits outweigh its risks.
While women have a lower risk for NAFLD, once present, the disease advanced more rapidly.
This connection may be attributable to lower iron levels.
Nearly a quarter of lean HIV-positive people in a recent study had NAFLD, and 16% of them developed fibrosis.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.